Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...
The S&P 500 and Nasdaq each set intraday records on Friday, but a majority of stocks were actually falling. The S&P 500 was up 0.7% after setting an intraday record at 7164.45. The Nasdaq was up 1.5% ...
Market breadth, not just technology stocks, is driving the current rally in equities, according to Brian Levitt, chief global market strategist at Invesco. Given the concentration of tech giants in ...
Speaking at WSJ Opinion Live in Washington, D.C., WSJ Editorial Page Editor Paul Gigot and SandboxAQ CEO Jack Hidary discuss Large Quantitative Models (LQMs) and their role in AI applications, the ...
What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...
Google announced on Thursday that it’s expanding its AI-powered conversational search feature, Search Live, globally to all languages and locations where AI Mode is available. With this expansion, ...
Jon McNeill, a serial founder, was the president of sales at Tesla from 2015 to 2018. At Tesla, McNeill helped develop a five-step framework that he says brought innovation to Tesla. The five-step ...
Google's John Mueller said that when it comes to AI Search and the changes that come with that, Google's core search algorithms, spam detection methods, spam policies, and other search systems do not ...
(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...
Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results